Loading
A phase 3 trial of Equecabtagene autoleucel, Daratumumab, Pomalidomide in multiple myeloma, run by Nanjing IASO Biotechnology Co., Ltd., now recruiting.
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) is a phase 3 interventional study registered as NCT06464991 by Nanjing IASO Biotechnology Co., Ltd., with 240 participants planned, started 2024-03-27 and due to reach its primary completion in 2027-08. Interventions recorded: Equecabtagene Autoleucel Injection, Daratumumab, Pomalidomide, Bortezomib, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Hospital-made CAR-T under one shared regulatory master file, Hospital-based CAR-T manufacturing at cost through a public network, Pomalidomide, Bortezomib.
Shares Pomalidomide, Daratumumab, Bortezomib, Dexamethasone.
Shares Hospital-made CAR-T under one shared regulatory master file, Hospital-based CAR-T manufacturing at cost through a public network, Relapsed or refractory multiple myeloma, CAR-T cell therapy.
Shares Pomalidomide, Daratumumab, Dexamethasone, Multiple myeloma.
Shares Pomalidomide, Daratumumab, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Pomalidomide, Daratumumab, Bortezomib, Dexamethasone.
Shares Pomalidomide, Bortezomib, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Pomalidomide, Bortezomib, Dexamethasone, Relapsed or refractory multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/